EGFR and neoplasm: Although the advent of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has markedly improved outcomes for patients with EGFR-mutant tumors, resistance development, tumor heterogeneity, and immune escape continue to hinder long-term efficacy [2–4].